Abstract:Fragile X syndrome (FXS) is a form of inherited mental retardation in humans that results from expansion of a CGG repeat in the Fmr1 gene. Recent studies suggest a role of astrocytes in neuronal development. However, the mechanisms involved in the regulation process of astrocytes from FXS remain unclear. In this study, we found that astrocytes derived from a Fragile X model, the Fmr1 knockout (KO) mouse which lacks FMRP expression, inhibited the proper elaboration of dendritic processes of neurons in vitro. Furthermore, astrocytic conditioned medium (ACM) from KO astrocytes inhibited proper dendritic growth of both wild-type (WT) and KO neurons. Inducing expression of FMRP by transfection of FMRP vectors in KO astrocytes restored dendritic morphology and levels of synaptic proteins. Further experiments revealed elevated levels of the neurotrophin-3 (NT-3) in KO ACM and the prefrontal cortex of Fmr1 KO mice. However, the levels of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF) were normal. FMRP has multiple RNA-binding motifs and is involved in translational regulation. RNA-binding protein immunoprecipitation (RIP) showed the NT-3 mRNA interacted with FMRP in WT astrocytes. Addition of high concentrations of exogenous NT-3 to culture medium reduced the dendrites of neurons and synaptic protein levels, whereas these measures were ameliorated by neutralizing antibody to NT-3 or knockdown of NT-3 expression in KO astrocytes through short hairpin RNAs (shRNAs). Prefrontal cortex microinjection of WT astrocytes or NT-3 shRNA infected KO astrocytes rescued the deficit of trace fear memory in KO mice, concomitantly decreased the NT-3 levels in the prefrontal cortex. This study indicates that excessive NT-3 from astrocytes contributes to the abnormal neuronal dendritic development and that astrocytes could be a potential therapeutic target for FXS.

The Study of FXR1P-Interacting Mrna

The Interaction Between IQCE Mrna and FXR1P in Yeast Three-Hybrid System

Fragile X Mental Retardation Protein Modulates the Stability of Its M6a-Marked Messenger RNA Targets.

The molecular biology of FMRP: new insights into fragile X syndrome

Excessive astrocyte-derived neurotrophin-3 contributes to the abnormal neuronal dendritic development in a mouse model of fragile X syndrome.

FMRP Acts As a Key Messenger for Dopamine Modulation in the Forebrain

Increased Coupling Of Caveolin-1 And Estrogen Receptor Alpha Contributes To The Fragile X Syndrome

Identification of Differentially Expressed Micrornas and Their Target Genes in the Hippocampal Tissues of Fmr1 Knockout Mice.

Fragile X Proteins FMRP and FXR2P Control Synaptic GluA1 Expression and Neuronal Maturation Via Distinct Mechanisms

Integrated Transcriptome Analysis of Human Ips Cells Derived from a Fragile X Syndrome Patient During Neuronal Differentiation

An in-depth review of the function of RNA-binding protein FXR1 in neurodevelopment

Gene Therapy Using Human FMRP Isoforms Driven by the Human FMR1 Promoter Rescues Fragile X Syndrome Mouse Deficits.

Computational Identification and Experimental Validation of MicroRNAs Binding to the Fragile X Syndrome Gene Fmr1

Opto-CLIP reveals dynamic FMRP regulation of mRNAs upon CA1 neuronal activation

FMRP(1–297)-tat restores ion channel and synaptic function in a model of Fragile X syndrome

Genome-wide Binding and Transcriptome Analysis of Human Farnesoid X Receptor in Primary Human Hepatocytes.

FMRP links optimal codons to mRNA stability in neurons

Identification of a molecular locus for normalizing dysregulated GABA release from interneurons in the Fragile X brain

Structural Studies Of The Tandem Tudor Domains Of Fragile X Mental Retardation Related Proteins Fxr1 And Fxr2

Lack of FMRP in the retina: Evidence of a retinal specific transcriptomic profile

FMRP regulates miR196a-mediated repression of HOXB8 via interaction with the AGO2 MID domain.